Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
BeiGene
Lin Shen; Ken Kato; Sung-Bae Kim; Jaffer A Ajani; Kuaile Zhao; Zhiyong He; Xinmin Yu; Yongqian Shu; Qi Luo; Jufeng Wang; Zhendong Chen; Zuoxing Niu; Longzhen Zhang; Tienan Yi; Jong-Mu Sun; Jianhua Chen; Guohua Yu; Chen-Yuan Lin; Hiroki Hara; Qing Bi; Taroh Satoh; Roberto Pazo-Cid; Hendrick-Tobias Arkenau; Christophe Borg; Florian Lordick; Liyun Li; Ningning Ding; Aiyang Tao; Jingwen Shi; Eric Van Cutsem; RATIONALE-302 Investigators